147610-84-2

Usage

Uses

Used in Pharmaceutical Industry:
6-Benzyl 1-ethyl 6-azaspiro[2.5]octane-1,6-dicarboxylate is utilized as a potential pharmaceutical agent for its diverse biological activities. The spirocyclic structure of the compound allows it to interact with various biological targets, making it a candidate for the development of new drugs.
Used in Drug Development:
In drug development, 6-benzyl 1-ethyl 6-azaspiro[2.5]octane-1,6-dicarboxylate serves as a chemical scaffold for the design and synthesis of new therapeutic agents. Its unique structure and functional groups can be modified to enhance its pharmacological properties and target specific diseases.
Further research and investigation into the properties and potential uses of 6-benzyl 1-ethyl 6-azaspiro[2.5]octane-1,6-dicarboxylate are necessary to fully explore its capabilities and applications in various fields.

Upstream product

• 1774-47-6 trimethylsulfoxonium iodide 
• 82244-11-9 ethyl-1-carbobenzoxy-Δ^4,α-piperidine-4-acetate 
• 623-73-4 diazoacetic acid ethyl ester 
• 138163-12-9 benzyl 4-methylene-1-piperidinecarboxylate 

Downstream Products

• 147610-85-3 6-(benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid 
• 1088497-66-8 (4-cyclohexylmethyl-piperazin-1-yl)-[6-(tetrahydro-pyran-4-yl)-6-aza-spiro[2.5]oct-1-yl]-methanone 
• 1088497-82-8 (4-cyclohexyl-piperazin-1-yl)-((R)-6-phenethyl-6-aza-spiro[2.5]oct-1-yl)-methanone 
• 1088497-81-7 (4-cyclohexyl-piperazin-1-yl)-((S)-6-phenethyl-6-aza-spiro[2.5]oct-1-yl)-methanone 
• 1088498-31-0 (R)-1-(4-cyclobutyl-piperazine-1-carbonyl)-6-aza-spiro[2.5]octane-6-carboxylic acid benzyl ester 
• 1088498-29-6 (S)-1-(4-cyclobutyl-piperazine-1-carbonyl)-6-aza-spiro[2.5]octane-6-carboxylic acid benzyl ester 
• 1088498-30-9 1-(4-cyclobutyl-piperazine-1-carbonyl)-6-aza-spiro[2.5]octane-6-carboxylic acid benzyl ester 
• 1088498-05-8 (4-cyclobutyl-piperazin-1-yl)-[6-(4-methoxy-phenyl)-6-aza-spiro[2.5]oct-1-yl]-methanone 
• 1088498-22-9 (4-methyl-piperazine-1-carbonyl)-6-aza-spiro[2.5]octane-6-carboxylic acid benzyl ester 
• 1088497-68-0 (4-methyl-piperazin-1-yl)-[6-((E)-3-phenyl-allyl)-6-aza-spiro[2.5]oct-1-yl]-methanone 
• 1088498-32-1 1-(piperazine-1-carbonyl)-6-aza-spiro[2.5]octane-6-carboxylic acid benzyl ester 
• 1088497-69-1 (4-methyl-1-piperazin-1-yl)-(6-phenethyl-6-aza-spiro[2.5]oct-1-yl)-methanone 

Relevant academic research and scientific papers

ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES

The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity particularly involved in the development and maintenance of persistent or chronic pain, and / or neurological disorders. These novel compounds are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which these ion channels are involved. The invention is also directed towards pharmaceutical formulations comprising these compounds and the uses of these compounds.

Discovery of spirofused piperazine and diazepane amides as selective histamine-3 antagonists with in vivo efficacy in a mouse model of cognition

A new series of potent and selective histamine-3 receptor (H3R) antagonists was identified on the basis of an azaspiro[2.5]octane carboxamide scaffold. Many scaffold modifications were largely tolerated, resulting in nanomolar-potent compounds in the H3R functional assay. Exemplar compound 6s demonstrated a selective profile against a panel of 144 secondary pharmacological receptors, with activity at only σ2 (62% at 10 μM). Compound 6s demonstrated free-plasma exposures above the IC50 (～50×) with a brain-to-plasma ratio of ～3 following intravenous dosing in mice. At three doses tested in the mouse novel object recognition model (1, 3, and 10 mg/kg s.c.), 6s demonstrated a statistically significant response compared with the control group. This series represents a new scaffold of H3 receptor antagonists that demonstrates in vivo exposure and efficacy in an animal model of cognition.

SPIROCYCLOPROPYL PIPERIDINE DERIVATIVES

Disclosed herein is at least one piperidine derivative, at least one pharmaceutical composition comprising at least one piperidine derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith